Analyst Viewpoint
Changing dietary patterns and sedentary lifestyles have driven the incidence of cardiovascular diseases worldwide. Consequently, key cardiovascular drugs manufacturers are focusing on the development of various drugs with enhanced efficacy and lesser side-effects to enable timely treatment of cardiovascular diseases. This is estimated to drive the cardiovascular drugs market growth during the forecast period.
Rise in aging population, greater understanding about heart disease, and increase in R&D on the introduction of novel therapeutics are also fueling market progress. Moreover, rise in awareness programs about prevention and treatment of cardiovascular ailments is expected to propel the market in the next few years. However, stringent regulations on drug approval and entry are projected to hamper the future prospects of cardiovascular drugs market growth.
Significant rise in the number of patients with cardiovascular diseases is a matter of global concern. Various types of cardiovascular drugs are prescribed to treat conditions related to the cardiovascular system, which includes the heart and blood vessels. In December 2022, the American College of Cardiology stated that cardiovascular diseases accounted for 185 million disability-adjusted life years (DALYs) in 2021. Therefore, rise in need to combat cardiovascular ailments is expected to drive the cardiovascular drugs market during the forecast period.
Hypertension, if left undetected or untreated, significantly increases the risk of developing cardiovascular disease. High blood pressure accounts for about half of all heart disease- and stroke-related deaths worldwide. The WHO has set a goal to reduce prevalence of hypertension by 30%, globally, by the year 2030. Increase in research on the development of high efficacy blood pressure medications is expected to fuel the cardiovascular drugs market size in the coming years.
Frequent cardiovascular drug recalls are likely to hamper the cardiovascular drugs market outlook during the forecast period. For instance, in September 2022, the US FDA announced that Golden State Medical Supply (GSMS) would be recalling two common cardiovascular medications due to mixed-up labeling. They were atenolol to treat hypertension and clopidogrel to reduce risk of acute myocardial infarction (AMI).
Increase in availability of substitute treatments and products restrains the demand for cardiovascular pharmaceuticals. Moreover, high cost of treatment and medication is also anticipated to hamper the demand for heart strengthening medication.
As per the World Health Organization (WHO), 17.9 million individuals succumb to cardiovascular diseases every single year. It further states that 33% of these deaths are witnessed prematurely in those aged below 70. Consequently, companies in cardiovascular drugs are engaging in excessive research to introduce effective cardiovascular drugs, followed by frequent approvals by regulating authorities, which in turn is likely to positively influence the cardiovascular drugs market forecast in the next few years.
In August 2021, the US FDA approved Jardiance (empagliflozin) 10 mg for reducing risk of cardiovascular death. It is also prescribed for adults suffering from reduced ejection fraction (HFrEF). Additionally, in May 2022, Zydus Worldwide DMCC received a tentative approval from the US FDA for marketing Selexipag tablets used for treating pulmonary arterial hypertension (PAH) in adults. In February 2022, the US FDA approved Norliqva (amlodipine) oral solution to treat hypertension in adults and those aged 6 and above for lowering blood pressure. These blood pressure medications are expected to fuel the demand for heart disease medications in the next few years.
The need for these medications could be gauged from data released by the American College of Cardiology in December 2022, stating that almost 2,770 DALYs per 100K persons worldwide pertaining to cardiovascular diseases were an outcome of high blood pressure.
Heart strengthening medication encompasses intake of various advanced drugs to address diverse needs regarding treatment of cardiovascular diseases. Lipitor is amongst the highest-selling cardiovascular drugs. However, presently, awareness about this drug is low in developing countries till date. In June 2023, the Asia Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was formed with the objective of raising awareness about cardiovascular health at domestic as well as regional forums in Asia Pacific.
At the global level, The National Heart, Lung, and Blood Institute (NHLBI) organized a campaign, ‘The Heart Truth’, to boost awareness about heart disease and related risk factors amongst women worldwide. Therefore, surge in number of awareness campaigns is expected to drive cardiovascular drugs industry during the forecast period.
According to the latest cardiovascular drugs market analysis, North America accounted for the largest share of demand for cardiovascular drugs due to growing incidences of cardiovascular diseases in the U.S. According to the National Center for Biotechnology Information, 7.9 million and 9 million individuals in the U.S. have suffered from heart attacks and angina pectoris, respectively, till date, and the figure is expected to increase at a notable pace during the forecast period.
Various research & development activities are being by undertaken prominent pharmaceutical players to develop effective cardiovascular drugs. One such drug is Leqvio, developed by Novartis. It is the first and sole small interfering RNA (siRNA) therapy devised for lowering low-density lipoprotein cholesterol (LDL) with two doses/year after initial doses for the first three months. Such innovations in cardiovascular drug therapies are expected to boost North America’s cardiovascular drug market share during the forecast period.
As per the European Society of Cardiology, cardiovascular diseases account for 3.9 million fatalities in Europe every year. Measures to prevent these deaths and cure existing patients on time are expected to drive cardiovascular drugs market value in Europe during the forecast period. These measures include extensive research about pharmaceuticals related to cardiovascular ailments and upgrade of existing heart disease medications.
As per the National Institute of Health, cardiovascular diseases accounted for 35% of total fatalities in Asia in 2019. Increase in incidence of cardiovascular diseases in Asia Pacific due to rise in adoption of unhealthy lifestyle behaviors and surge in awareness campaigns about cardiac medication across developing economies in the region are anticipated to considerably boost the Asia Pacific cardiovascular drugs market in 2023.
As per the latest cardiovascular drugs market analysis, leading companies are following the latest market trends and focusing on the launch of generic drugs for heart failure, especially after expiry of patents of well-known drugs. Furthermore, key manufacturers are engaging in partnerships with research institutions to develop novel treatments and consolidate their position in the global market.
AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., and Takeda Pharmaceuticals Company Ltd are a few prominent cardiovascular drugs market manufacturers operating across the globe.
Key players in the cardiovascular drugs market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 142.8 Bn |
| Forecast (Value) in 2031 | US$ 195.6 Bn |
| Growth Rate (CAGR) | 3.8% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Cardiovascular Drugs Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
The global market was valued at US$ 142.8 Bn in 2022
It is projected to expand at a CAGR of 3.8% from 2023 to 2031
Rise in prevalence of cardiovascular ailments and surge in awareness about cardiovascular health
In terms of distribution, the hospital pharmacy segment held largest share in 2022
North America is estimated to dominate in the next few years
AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., and Takeda Pharmaceuticals Company Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiovascular Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Renin-Angiotensin System Blockers
6.3.1.1. ACE Inhibitors
6.3.1.2. Angiotensin Receptor Blockers
6.3.2. Beta Blockers
6.3.3. Diuretics
6.3.4. Anti-Clotting Agents
6.3.4.1. Anti-Coagulants
6.3.4.2. Platelet Aggregation Inhibitors
6.3.5. Antihyperlipidemics
6.3.6. Other Antihypertensive
6.3.7. Calcium Channel Blockers
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Hypertension
7.3.2. Hyperlipidemia
7.3.3. Coronary Artery Disease
7.3.4. Peripheral Artery Disease
7.3.5. Arrhythmia
7.3.6. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cardiovascular Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Renin-Angiotensin System Blockers
10.3.1.1. ACE Inhibitors
10.3.1.2. Angiotensin Receptor Blockers
10.3.2. Beta Blockers
10.3.3. Diuretics
10.3.4. Anti-Clotting Agents
10.3.4.1. Anti-Coagulants
10.3.4.2. Platelet Aggregation Inhibitors
10.3.5. Antihyperlipidemics
10.3.6. Other Antihypertensive
10.3.7. Calcium Channel Blockers
10.3.8. Others
10.4. Market Value Forecast, by Indication, 2017–2031
10.4.1. Hypertension
10.4.2. Hyperlipidemia
10.4.3. Coronary Artery Disease
10.4.4. Peripheral Artery Disease
10.4.5. Arrhythmia
10.4.6. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Cardiovascular Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Renin-Angiotensin System Blockers
11.3.1.1. ACE Inhibitors
11.3.1.2. Angiotensin Receptor Blockers
11.3.2. Beta Blockers
11.3.3. Diuretics
11.3.4. Anti-Clotting Agents
11.3.4.1. Anti-Coagulants
11.3.4.2. Platelet Aggregation Inhibitors
11.3.5. Antihyperlipidemics
11.3.6. Other Antihypertensive
11.3.7. Calcium Channel Blockers
11.3.8. Others
11.4. Market Value Forecast, by Indication, 2017–2031
11.4.1. Hypertension
11.4.2. Hyperlipidemia
11.4.3. Coronary Artery Disease
11.4.4. Peripheral Artery Disease
11.4.5. Arrhythmia
11.4.6. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Renin-Angiotensin System Blockers
12.3.1.1. ACE Inhibitors
12.3.1.2. Angiotensin Receptor Blockers
12.3.2. Beta Blockers
12.3.3. Diuretics
12.3.4. Anti-Clotting Agents
12.3.4.1. Anti-Coagulants
12.3.4.2. Platelet Aggregation Inhibitors
12.3.5. Antihyperlipidemics
12.3.6. Other Antihypertensive
12.3.7. Calcium Channel Blockers
12.3.8. Others
12.4. Market Value Forecast, by Indication, 2017–2031
12.4.1. Hypertension
12.4.2. Hyperlipidemia
12.4.3. Coronary Artery Disease
12.4.4. Peripheral Artery Disease
12.4.5. Arrhythmia
12.4.6. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Cardiovascular Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Renin-Angiotensin System Blockers
13.3.1.1. ACE Inhibitors
13.3.1.2. Angiotensin Receptor Blockers
13.3.2. Beta Blockers
13.3.3. Diuretics
13.3.4. Anti-Clotting Agents
13.3.4.1. Anti-Coagulants
13.3.4.2. Platelet Aggregation Inhibitors
13.3.5. Antihyperlipidemics
13.3.6. Other Antihypertensive
13.3.7. Calcium Channel Blockers
13.3.8. Others
13.4. Market Value Forecast, by Indication, 2017–2031
13.4.1.1. Hypertension
13.4.1.2. Hyperlipidemia
13.4.1.3. Coronary Artery Disease
13.4.1.4. Peripheral Artery Disease
13.4.1.5. Arrhythmia
13.4.1.6. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Renin-Angiotensin System Blockers
14.3.1.1. ACE Inhibitors
14.3.1.2. Angiotensin Receptor Blockers
14.3.2. Beta Blockers
14.3.3. Diuretics
14.3.4. Anti-Clotting Agents
14.3.4.1. Anti-Coagulants
14.3.4.2. Platelet Aggregation Inhibitors
14.3.5. Antihyperlipidemics
14.3.6. Other Antihypertensive
14.3.7. Calcium Channel Blockers
14.3.8. Others
14.4. Market Value Forecast, by Indication, 2017–2031
14.4.1. Hypertension
14.4.2. Hyperlipidemia
14.4.3. Coronary Artery Disease
14.4.4. Peripheral Artery Disease
14.4.5. Arrhythmia
14.4.6. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co. Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bayer AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Sanofi
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Boehringer Ingelheim GmbH
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. F. Hoffmann-La Roche Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Abbott Laboratories
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Gilead Sciences, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Johnson & Johnson
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Astellas Pharma, Inc.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Eli Lilly and Company
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. Otsuka Holdings Co., Ltd.
15.3.15.1. Company Overview
15.3.15.2. Product Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview
15.3.16. Takeda Pharmaceuticals Company Ltd.
15.3.16.1. Company Overview
15.3.16.2. Product Portfolio
15.3.16.3. SWOT Analysis
15.3.16.4. Financial Overview
15.3.16.5. Strategic Overview
List of Tables
Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Cardiovascular Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Cardiovascular Drugs Market Value Share, by Drug Class, 2022
Figure 04: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Cardiovascular Drugs Market Value Share, by Indication, 2022
Figure 06: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Cardiovascular Drugs Market Value Share, by Distribution Channel, 2022
Figure 08: Global Cardiovascular Drugs Market Value Share, by Region, 2022
Figure 09: Global Cardiovascular Drugs Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 11: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 12: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 13: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 16: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 22: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 23: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 25: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 26: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 32: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 35: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 40: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 41: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 44: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 50: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 52: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 53: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 58: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 59: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 62: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cardiovascular Drugs Market
*86 figures and 60 tables includes